Pharmacoeconomics and quality of life were major themes that resonated throughout the Fourth International Symposium on Oncology Pharmacy Practice. The following report, supplemented by information from the ISOPP IV Symposium, defines pharmacoeconomics research and describes the methods used to perform pharma coeconomic analyses and quality of life studies. Results of original pharmacoeconomic studies per formed in cancer patients are critiqued.
Cooke J.The health economics aspects of the management of cancer. J Oncol Pharm Practice. 1995;1(ISOPP IV Symposium Issue):30.
2.
Townsend RJPost-marketing drug research and development. Drug Intell Clin Pharm.1987;21:134-136.
3.
Draugalis JR, Bootman, JL, Larson LN, McGhan WFPharmacoeconomics. Current Concepts. Kalamazoo, Mich: The Upjohn Company; 1989.
4.
Emlet HE Jr. Use of cost-benefit analysis in solutions to national health problems . Presented at the 1986 Joint National Meeting of the Operations Research Society of America; May 1-3, 1968 ; San Francisco, Calif.
5.
Klarman HEApplication of cost/benefit analysis to health services and the special case of technologic innovation. Int J Health Serv.1974;4:325-352.
6.
Kissick WLCost-benefit studies in health planning in the U.S.AHealth Econ.1969;39-44.
7.
Smith WFCost-effectiveness and cost-benefit analyses for public health programs . Public Health Rep.1968;83:899-906.
8.
Stoddard GL, Drummond MFHow to read clinical journals, VII: to understand an economic evaluation (part A). Can Med Assoc J.1984;130:1428-1434.
9.
McGhan WF, Rowland CR, Bootman JLCost-benefit and cost-effectiveness: methodology for evaluating innovative pharmaceutical services. Am J Hosp Pharm.1978;35:133-140.
10.
Bootman JL, Rowland C., Wertheimer AICost-benefit analysis: a research tool for evaluating innovative health programs . Eval Health Professions.1979;2:129-154.
11.
Weinstein MC , Stason WBFoundations of cost/effectiveness analysis for health and medical practices. N Engl J Med.1977;296:716-721.
12.
Crystal R., Brewster A.Cost-benefit and cost-effectiveness analysis in the health field: an introduction . Inquiry.1966;3:3-13.
13.
Bungay KM, Ware JEMeasuring and monitoring health-related quality of life. Current Concepts . Kalamazoo, Mich: The Upjohn Company ; 1993.
14.
Dranitsaris G., Warr D., Puodziunas A.A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer.1995;3:183-189.
15.
Dranitsaris G., Sutcliffe SBEconomic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk Lymphoma.1995;17:139-145.
16.
Dranitsaris G., Tran TMEconomic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. J Oncol Pharm Practice. 1995;11 (ISOPP IV Symposium Issue): 14-15.
17.
Ascani L., Capri S., Carders C., et al. Cost analysis of a large outpatient department of oncology chemotherapy . J Oncol Pharm Practice. 1995; 1 (ISOPP IV Symposium Issue):40.
18.
Cella DF, Cherin EAQuality of life during and after cancer treatment. Compr Ther.1988;14(5):69-75.
